Krysten Soldan, RN
Memorial Sloan Kettering Cancer Center, New York, NYAuthored Items
Krysten Soldan, RN, Carolyn Johns, NP, Matthew H. Taylor, MD, Kathryn Gillis, PharmD, Robert Orlowski, MD, Min Ren, Vicky Makker
November 13, 2020 | November 2020 Vol 11, No 11
Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in endometrial carcinoma (EC) in a phase 1b/2 clinical trial (Study 111/KEYNOTE-146).
Last modified: November 13, 2020